Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out


March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect TMAU

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed
Follow MeBOResearch on Twitter

Blog Archive

Denver TMAU Test Lab survey click here
click to Read more/less

USA survey for anyone who wants to improve Denver TMAU test

begun : Dec22
end : no ending for now

A trainee genetic counselor is working at the Denver TMAU test lab. Probably as part of her training. As a project she wishes feedback on any aspect of the Denver TMAU test and process. You can fill in the survey and/or email her (email address is in survey). It's meant for USA people, but perhaps others can give their view too (as we have so few opportunities).

quote from her rareconnect post

"Hello all! I wanted to make you aware of a research study being conducted to better understand the experience and needs of individuals with trimethylaminuria with a goal of being able to create improved patient and healthcare provider education materials. Any participation is completely voluntary and all responses remain confidential. Feel free to use the contact information within the link with any questions or share the survey with others with TMAU."

see this post for more details

Tuesday, January 13, 2009

2008 dissertation paper on TMAU DNA : 8 out of 12 had no (known) mutations

This January 2008 dissertation by Jaffar Alfardan poses a few questions regarding the trimethylaminuria diagnosis. Probably more questions than answers. Dr Alfardan has/had an association with the University of Colorado Denver Health Sciences Center (UCDHSC), which is where Dr Fennessey works. For a few years now, Dr Fennesseys lab has been the lab in the USA where perhaps 99.9% of USA TMAU urine testing has been done (mostly by mail).

The object seems to have been to match 12 'phenotype' (urine test) TMAU sufferers with the 'genotype' (DNA) test. Only 4 out of 12 matched this objective (TMAU = autosomal recessive disorder : 2 mutant copies). They also found a 'new' mutant amongst those 4, indicating how the current database of mutations is likely an underestimate, and how little research is done in this area. Amongst the other 8, some seemingly were double heterozygous for known 'polymorphic' FMO3 DNA copies. Polymorphisms are more common and are regarded as 'variations' in efficiency, rather than mutants that are severe. But there were even some with only one polymorph (E158K). Possible reasons for this may be that some/many mutants are still to be discovered, and/or that polymorphisms can cause problems ... and even that it may be an autosomal dominant problem if certain copies are involved (e.g. E158K).

Presumably no follow-up will be done on the dissertation.

...There are limited studies of the sequence variants causing TMAU in the literature with most studies describing only one or two patients and lacking genotype-phenotype correlations. Also to date, there is no laboratory in the US or Europe that offers TMA genetic testing on a clinical basis. We have recently validated genetic testing in the University of Colorado DNA Diagnostic Laboratory. We have a database of a few dozen patients with a biochemical diagnosis of TMA at the University of Colorado at Denver Health Sciences Center (UCDHSC) which includes a few patients with the classical form of the disease. We have used the newly established clinical test in our institution to attempt to characterize the genotype (sequence variants including mutations and polymorphisms) of classical TMAU patients and to establish a genotype-phenotype (biochemical and clinical) association. The questionnaire results confirmed most of the previously reported epidemiological findings of TMAU and also indicated that TMAU patients use multiple intervention measures in attempt to control their symptoms with dietary control being most effective. Despite the complexity of intervention, most patients did not have any medical follow up and there was underutilization of specialist care. In a set of our patients, two deleterious mutations were identified in 4/12 patients including a novel T237P sequence variant, while the majority of our patients (8/12) did not reveal any mutations. Some of the latter were double heterozygous for the E158K and E308G polymorphisms which could explain a mild phenotype while others had only the E158K variant which raised the question of undetected mutations. These results indicate that further experiments are needed to further delineate the full mutational spectrum of the FMO3 gene.

points of interest:

The 'textbook' explanation for trimethylaminuria would be it is autosomal recessive (2 mutations of the gene), but 8 of the 12 had no known mutations, and a new mutation was found. Polymoprphisms are usually regarded as being less severe and more common (more than 1% population), whereas mutations are often regarded severe and rare (such as null-allelle, where they are deemed almost useless), but the definitions are ambiguous. Perhaps the terms will make more sense as we learn more about DNA terminology. However, the main point here is that the 'textbook' explanation of trimethylaminuria being autosomal recessive wasn't strongly proven in this paper. The main problem for sufferers however, is that the dissertation was likely a one-off, and no further research is likely forthcoming on this subject in the near future. So the 'rare problem' tag will likely be around a while. Probably the best approach is for sufferers to become the motivator of research and awareness amongst decision makers, rather than the current situation.

Mutations and polymorphisms explained glossary : double heterozygous


Post a Comment